Tbilisi, Georgia

Vakhtang Beridze

This inventor holds 6 USPTO granted patents. Top assignees: Phagelux (Canada) Inc., Precisio Biotix Therapeutics, Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vakhtang Beridze. Retrieved from https://idiyas.com/inventor/vakhtang-beridze

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2020-2026

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Journey of Vakhtang Beridze

Introduction: Vakhtang Beridze, a pioneering inventor hailing from Tbilisi, Georgia, has made significant contributions to the world of innovations with his creative mind and dedication to progress.

Latest Patents: Vakhtang Beridze's latest patents include groundbreaking inventions in the field of renewable energy technologies, specifically focusing on solar power optimization and energy storage solutions.

Career Highlights: Throughout his illustrious career, Vakhtang Beridze has been recognized for his innovative spirit, receiving numerous awards for his contributions to sustainable technologies and clean energy initiatives.

Collaborations: Vakhtang Beridze has collaborated with leading research institutions and universities worldwide to further advance his inventions, fostering a culture of innovation and knowledge-sharing within the scientific community.

Conclusion: In conclusion, Vakhtang Beridze stands as a beacon of inspiration for aspiring inventors, showcasing the power of creativity and perseverance in driving meaningful change through technological advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…